

This article was downloaded by:

On: 23 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Liquid Chromatography & Related Technologies

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597273>

Isolation and Purification of Kava Lactones by High Performance Centrifugal Partition Chromatography

J. R. Mikell^a; B. T. Schaneberg^a; I. A. Khan^a

^a Department of Pharmacognosy, National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, Mississippi, USA

Online publication date: 10 September 2003

To cite this Article Mikell, J. R. , Schaneberg, B. T. and Khan, I. A.(2003) 'Isolation and Purification of Kava Lactones by High Performance Centrifugal Partition Chromatography', *Journal of Liquid Chromatography & Related Technologies*, 26: 18, 3069 – 3074

To link to this Article: DOI: 10.1081/JLC-120025423

URL: <http://dx.doi.org/10.1081/JLC-120025423>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Isolation and Purification of Kava Lactones by High Performance Centrifugal Partition Chromatography

J. R. Mikell, B. T. Schaneberg, and I. A. Khan*

Department of Pharmacognosy, National Center for Natural Products
Research, School of Pharmacy, The University of Mississippi,
University, Mississippi, USA

ABSTRACT

Kava kava (*Piper methysticum*) is currently used in a variety of herbal and homeopathic preparations to induce relaxation, treat anxiety, or induce sleep. The pharmacologically active compounds consist of a group of structurally related lactone derivatives that are concentrated in the roots, rhizomes, and root stems. The major constituents responsible for 95% of the total pharmacological activity are desmethoxyyangonin, dihydrokavain, yangonin, kavain, dihydromethysticin, and methysticin. The concern over the possible hepatotoxicity of kava has led regulatory agencies in countries such as Germany, Switzerland, France, Canada, the United Kingdom, as well as the United States to respond by warning consumers about the potential risks of kava use, or by removing kava-containing

*Correspondence: I. A. Khan, Department of Pharmacognosy, National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, University, MS 38677, USA; E-mail: ikhan@olemiss.edu.

3069

DOI: 10.1081/JLC-120025423
Copyright © 2003 by Marcel Dekker, Inc.

1082-6076 (Print); 1520-572X (Online)
www.dekker.com

MARCEL DEKKER, INC.
270 Madison Avenue, New York, New York 10016



products from the marketplace. The high demand for purified kavalactones has emerged to facilitate necessary testing to investigate the rising concern over these cases of liver toxicity. A separation method using high performance centrifugal partition chromatography (HPCPC) has been developed for the isolation of each kava lactone from a CO₂ extract of *P. methysticum* in a single chromatographic run.

Key Words: Kava lactones; Centrifugal partition chromatography; HPCPC; *Piper methysticum*; Methysticin; Dihydromethysticin; Kawain; Dihydrokawain; Yangonin; Desmethoxyyangonin.

INTRODUCTION

Kava kava (*Piper methysticum*) has been used for centuries in social and religious settings throughout the Pacific islands of Micronesia. Fresh or dried root is crushed with water, filtered, and the liquid is then consumed as a beverage for its intoxicating, calming effects that promote sociability.^[1] Due to the observed calming effects, dietary supplements containing kava kava were used in North America and Europe for anxiety disorders, stress disorders, nervous tension, and restlessness.^[2,3] Today, several extracts are standardized for the biologically active kavalactones considered responsible for kava kava's calming effects. Although, clinical studies of kava kava in the last decade have shown it to be very effective, well tolerated, and non-addictive at therapeutic dosages, potential side effects can occur when very high doses (100–300 mg/daily) are taken for extended periods.^[3,4] These can include an allergic skin reaction, a reversible gastrointestinal disturbance, as well as dopamine antagonism.^[2] Recently, there has been several adverse event reports pertaining to kava kava in Europe and the United States due to severe cases of hepatotoxicity. According to the FDA, kava-containing products have been associated with liver-related injuries (including hepatitis, cirrhosis, and liver failure) in over 25 reports of adverse events in other countries.^[5] A case of recurring necrotizing hepatitis was reported in Germany in 1998 and at the end of 2000 in Switzerland, a patient was subjected to a liver transplant because he developed stage IV encephalopathy associated with kava-kava consumption at 210–280 mg kavalactones/day.^[6,7] This concern over the possible hepatotoxicity of kava has led to regulatory agencies in countries such as Germany, Switzerland, France, Canada, the United Kingdom, as well as the United States to either warn consumers about the potential risk of kava use or remove kava-containing products from the marketplace.^[8] However, the evidence is inadequate to implicate kava as the responsible agent since a direct causal relationship of the liver toxicity with kava has not been established.

Since kava has yet to be proven safe or not, further studies must be undertaken. This has led to the high demand for purified kavalactones (Fig. 1)






Figure 1. Structures of the kavalactones.

to facilitate necessary testing. A relatively simple and time efficient separation method for the isolation of the kavalactones^[1-6] has been developed using high performance centrifugal partition chromatography (HPCPC).

EXPERIMENTAL

Materials

The supercritical CO₂ extract of *P. methysticum* was provided by Alden Botanica (Moreno Valley, CA). Solvents were Fisher Scientific chromatographic grade (Suwanee, Georgia).



Methods

High Performance Centrifugal Partition Chromatography

CPC experiments were performed using a High Performance Centrifugal Partition Chromatograph, Series 1000 HPCPC Column Module (Sanki Engineering Limited, Nagaokakyo Kyoto, Japan). The solvents were pumped into the HPCPC rotating 1100 rpm with a Beckman 110B Solvent Delivery Module. Flow rate was set at 3 mL/min. Fractions were collected with a Bio-Rad Model 2110 fraction collector. A 1 g sample of kava extract was dissolved in 2.5 mL of a 50 : 50 mixture of both the organic phase and aqueous phase. A solvent system consisting of (3 : 1 : 2 : 1) (hexanes : ethyl acetate : methanol : water) separated five of the kavalactones collecting 300, 10 mL fractions. A solvent system of (4 : 1 : 3 : 1), (hexanes : acetone : methanol : water) separated all six kavalactones collecting 1145, 10 mL fractions. Both solvent systems were run in the ascending mode with the organic layer as the mobile phase and the aqueous layer as the stationary phase. Fractions were analyzed by TLC on silica gel, employing 30% ethyl acetate and 70% hexanes and developing the plate twice. The plates were sprayed with anisaldehyde spray reagent. Fractions were compared to pure compounds as standards. The fractions were also analyzed for purity and identity by HPLC.

Analytical High Performance Liquid Chromatography

HPLC was performed on a Waters Alliance 2695 Separations Module equipped with a Waters 996 photodiode array detector (Milford, MA). Separations were carried out on a Luna C8^[2] reverse phase column (100 × 4.6 mm, 3 μm particle size) from Phenomenex (Torrance, CA). The mobile phase was mixed online to give a mixture of water/acetonitrile/reagent alcohol (65/20/15). The isocratic system had a flow rate of 0.75 mL/min with a 5 μL injection volume at 40°C. Run time was 20 min at a detection wavelength of 246 nm. The column was washed with methanol for 5 min and then re-equilibrated for 10 min. Samples (5 mg each) were dissolved in methanol (5 mL) and filtered through a Nylon 0.45 μm membrane filter into a HPLC vial for analysis.

Partition Coefficient Determination

About 10.0 mg of kava kava extract was partitioned between 2 mL upper phase and 2 mL lower phase of the solvent mixture; hexanes : acetone : methanol : water (4 : 1 : 3 : 1). The resulting layers were analyzed by HPLC for concentration of each kavalactone.



Table 1. Partition coefficients for (1–6) in solvent mixture.

Compound	Partition coefficient
1	0.071
2	0.053
3	0.047
4	0.032
5	0.025
6	0.015

Hexanes : acetone : methanol : water (4 : 1 : 3 : 1).

RESULTS AND DISCUSSION

A relatively simple method for the isolation of all six kavalactones has been developed using HPCPC. This method purifies the kavalactones in a single chromatographic run using a hexanes:acetone:methanol:water, (4:1:3:1), solvent system. The partition coefficients of the kavalactones are summarized in Table 1. The six kavalactones are structurally very similar and chromatograph very closely on silica gel. The results obtained with the HPCPC method are substantially better than those from the conventional column chromatography in terms of peak resolution. Traditional chromatography using silica gel does not always afford fractions of purified kavalactones since the lactones frequently coelute. A solvent system, which employs (hexanes:ethyl acetate:methanol:water) (3:1:2:1) was able to purify five of the kavalactones and is relatively shorter to run as compared to the (hexanes:acetone:methanol:water) solvent system. The kavalactone yangonin could not be separated from kavain with this particular system, which would be preferable to use when isolation of yangonin was not a required purified product. The HPCPC was employed to separate a 1 g extract of kava kava. Using the hexanes:acetone:methanol:water solvent system afforded purified fractions of desmethoxyyangonin, 53.9 mg; dikydrokavain, 168.2 mg; yangonin, 29.5 mg; kavain, 138.0 mg; dihydromethysticin, 71.0 mg; methysticin, 50.7 mg. Upon recrystallization all had purities in excess of 98%.

ACKNOWLEDGMENTS

This research was funded in part by the United States Department of Agriculture, Agricultural Research Service Specific Cooperative Agreement



No. 58-6408-2-0009 and the Botanical Dietary Supplements: Science Base for Authentication funded by Food and Drug Administration grant number FD-U-002071-01.

REFERENCES

1. Reeder, S.; Cupp, M.J. *Kava. Toxicology and Clinical Pharmacology of Herbal Products*; Humana Press Inc.: Totowa, New Jersey, 2000; 31–41.
2. Bilia, A.; Gallori, S.; Vincieri, F. Kava-kava and anxiety: growing knowledge about the efficacy and safety. *Life Sci.* **2002**, *70* (2), 581.
3. Ernst, E. The risk-benefit profile of commonly used herbal therapies: ginko, St. John's wort, ginseng, echinacea, saw palmetto, and kava. *Ann. Intern. Med.* **2002**, *136*, 42–53.
4. Singh, Y.N.; Singh, N.N. Therapeutic potential of kava in the treatment of anxiety disorders. *CNS Drugs* **2002**, *16* (11), 731.
5. *Kava-Containing Dietary Supplements may be Associated with Severe Liver Injury, March 25, 2002*, Food and Drug Administration Consumer Advisory; Department of Food and Drug Administration: Washington, D.C., 2002.
6. Straho, S.; Ehret, V.; Dahm, H.H.; Maier, K.P. Necrotizing hepatitis after taking herbal remedies. *Deut. Med. Wochenschr.* **2002**, *123* (47), 1410–1414.
7. Escher, M.; Desmeules, J.; Giostra, E.; Mentha, G. Hepatitis associated with kava, a herbal remedy for anxiety. *British Med. J.* **2001**, *322*, 139.
8. *Hepatic Toxicity Possibly Associated with Kava-Containing Products—United States, Germany, and Switzerland, 1999–2002*, Morbidity and Mortality Weekly Report Nov. 9, 2002; Center for Disease Control and Prevention: Atlanta, Georgia, 2002; Vol. 51, Issue 47, 1065–1067.

Received March 20, 2003

Accepted April 9, 2003

Manuscript 6139

